Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.
Public Library of Science (PLoS)
MetadataShow full item record
Fillmore, N., Bell, S., Shen, C., Nguyen, V., La, J., Dubreuil, M., Strymish, J., et al. (2021). Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.. PLoS One, 16 (10), e0259061. https://doi.org/10.1371/journal.pone.0259061
Effective, low-cost therapeutics are needed to prevent and treat COVID-19. Severe COVID-19 disease is linked to excessive inflammation. Disulfiram is an approved oral drug used to treat alcohol use disorder that is a potent anti-inflammatory agent and an inhibitor of the viral proteases. We investigated the potential effects of disulfiram on SARS-CoV-2 infection and disease severity in an observational study using a large database of clinical records from the national US Veterans Affairs healthcare system. A multivariable Cox regression adjusted for demographic information and diagnosis of alcohol use disorder revealed a reduced risk of SARS-CoV-2 infection with disulfiram use at a hazard ratio of 0.66 (34% lower risk, 95% confidence interval 24-43%). There were no COVID-19 related deaths among the 188 SARS-CoV-2 positive patients treated with disulfiram, in contrast to 5-6 statistically expected deaths based on the untreated population (P = 0.03). Our epidemiological results suggest that disulfiram may contribute to the reduced incidence and severity of COVID-19. These results support carefully planned clinical trials to assess the potential therapeutic effects of disulfiram in COVID-19.
External DOI: https://doi.org/10.1371/journal.pone.0259061
This record's URL: https://www.repository.cam.ac.uk/handle/1810/330303
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/